NEW YORK, Sept. 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Endo International plc (NASDAQ:ENDP) between November 30, 2012 and July 6, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Bier v. Endo International plc, et al. (Case No. 2:17-cv-03711-TJS) in the USDC for the Eastern District of Pennsylvania. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra-sbm/endo-international-plc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana ER. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
If you suffered a loss in Endo you have until October 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Apple Turns 50: From Garage Startup to AI Crossroads
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 



